ストックスクリーナーアプリを入手
1.15
3.60%
0.04
前日終値:
$1.11
開ける：
$1.08
24時間の取引高:
398.71K
Relative Volume:
1.14
時価総額：
$51.60M
収益：
$19.94M
当期純損益:
$-37.37M
株価収益率:
-1.1058
EPS:
-1.04
ネットキャッシュフロー:
$-33.38M
1週間 パフォーマンス:
+3.60%
1か月 パフォーマンス:
+34.60%
6か月 パフォーマンス:
-39.47%
1年 パフォーマンス:
-77.71%
1日の値動き範囲:
$1.06
$1.16
1週間の範囲:
$1.02
$1.23
52週間の値動き範囲:
$0.595
$5.73
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
HOWL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.15 | 49.81M | 19.94M | -37.37M | -33.38M | -1.04 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-24 | 開始されました | Wedbush | Outperform |
| 2023-06-06 | 再開されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-25 | 開始されました | Evercore ISI | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-25 | 開始されました | Jefferies | Buy |
| 2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential By Investing.com - Investing.com Nigeria
Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com Australia
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewswire
Breakthrough Skin Cancer Treatment: Patient Cancer-Free After 1 Year in Revolutionary IL-2 Drug Trial - Stock Titan
Dimensional Fund Advisors LP Cuts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Receives Nasdaq Deficiency Notice - TipRanks
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit - GlobeNewswire
Wedbush Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $6.00 - Defense World
Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024) - Yahoo Finance
Wedbush Adjusts Price Target on WEREWOLF THERAPEUTICS (HOWL) to USD 6.00 | HOWL Stock News - GuruFocus
H.C. Wainwright cuts Werewolf Therapeutics target to $10 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Werewolf Therapeutics target to $10 - Investing.com Australia
Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating - marketscreener.com
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Q1 2025 Financial Results - TipRanks
Werewolf Therapeutics (HOWL) Advances Clinical Trials and Expands Educational Initiatives | HOWL Stock News - GuruFocus
Werewolf Therapeutics Announces Q1 2025 Financial Results - TipRanks
Werewolf Therapeutics Announces Progress in Clinical Trials and Financial Updates for Q1 2025 - Nasdaq
Renaissance Technologies LLC Decreases Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
JPMorgan Chase & Co. Raises Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics (HOWL) Showcases Innovative IBD Treatment Developments | HOWL Stock News - GuruFocus
Werewolf Therapeutics reports progress on IBD treatment - Investing.com Australia
Werewolf Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Werewolf Therapeutics Presents New Preclinical Data Further - GlobeNewswire
Breakthrough: New IBD Drug Overcomes Major Treatment Hurdle in Preclinical Tests - Stock Titan
Cancer Immunotherapy Pioneer Werewolf Therapeutics Sets Two Major Investor Conference Appearances - Stock Titan
Werewolf Therapeutics (HOWL) Projected to Post Earnings on Friday - American Banking and Market News
Geode Capital Management LLC Purchases 16,569 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics director Luke Evnin sells $2,546 in stock By Investing.com - Investing.com Nigeria
Werewolf Therapeutics director Luke Evnin sells $2,546 in stock - Investing.com Australia
Werewolf therapeutics sees $4,605 stock sale by major investor By Investing.com - Investing.com
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline - Yahoo Finance
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Friday - Defense World
Werewolf Therapeutics stock maintains $4 target, Market Outperform By Investing.com - Investing.com India
Werewolf Therapeutics stock maintains $4 target, Market Outperform - Investing.com
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewswire
Cancer Drug Developer Werewolf Therapeutics Strengthens Leadership Team Amid Promising Clinical Results - Stock Titan
Werewolf Therapeutics (HOWL) Appoints Steven Bloom as Chief Business Officer | HOWL Stock News - GuruFocus
Werewolf Therapeutics stock hits 52-week low at $0.85 - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $0.85 By Investing.com - Investing.com South Africa
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Werewolf Therapeutics Reveals Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
17.27%
1.06%
大文字化:
|
ボリューム (24 時間):